Scientists have taken an important step toward the development of a potential new treatment for treating Shiga toxin-producing E coli (STEC), the bacteria associated with severe food poisoning. 

The findings – led by the University of Glasgow and published in Antimicrobials and Resistance – demonstrate, for the first time, the use of an antivirulence drug called Aurodox, a potential alternative to traditional antibiotic treatment, to be an effective treatment when used in mice models of STEC. 

The STEC strain of E coli is often transmitted by eating contaminated food or undercooked meat. 

STEC infections are a significant threat to public health, with an estimated 2.8 million cases globally per year, with modern food supply infrastructure and climate change increasing the incidence of large, multinational outbreaks. 

Scotland currently has one of the highest global incidences of STEC infections – three times higher than the rest of the UK – and treatment options remain limited and difficult, as antibiotics can make the disease worse by releasing a potent toxin into the infected person’s gut and disrupting beneficial gut bacteria. 

Children in Scotland account for almost half of all cases of STEC, with some at risk of developing haemolytic uraemic syndrome (HUS), a potentially-fatal clinical syndrome that can lead to acute kidney failure.  

Adults may also develop a similar condition called thrombotic thrombocytopenic purpura (TTP). 

Beneficial impact on gut bacteria

The study results suggest that Aurodox may influence the gut microbiome in a beneficial way, unlike traditional antibiotics, making it a promising alternative for treating STEC without major disruptions to gut bacteria. 

Professor Andrew Roe, Professor of Molecular Microbiology at the University of Glasgow and lead author of the study, said: “Our findings in mice models are a huge step forward in the development of a new treatment for Shiga toxin-producing E coli (STEC), which is a potentially fatal bacteria bug that is difficult to treat. 

“The next steps will be to test the broader applications of Aurodox on more pathogens that use the same colonisation system and to work with pharmaceutical companies to test this as a treatment in patients. It’s still a long journey but this is such an important milestone.”

Diana Spencer, Senior Digital Content Editor, DDW